<DOC>
	<DOC>NCT02477670</DOC>
	<brief_summary>The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Patients who meet DSMIVTR diagnostic criteria for schizophrenia using the M.I.N.I. version 6.0. Patients must meet PANSS criteria Patients currently receiving atypical antipsychotics are eligible provided they are on a stable dose Patients with current major depressive disorder (MDD) Patients with extrapyramidal syndrome secondary to their ongoing antipsychotic medication Patients currently using anticholinergic medications Recent inpatient hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Negative Symptoms</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>AVP-786</keyword>
</DOC>